Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.45 |
| ▸ | RARB | P10826 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085628 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 | |
| SCHEMBL1200763 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 | |
| SCHEMBL1200970 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 | |
| SCHEMBL1201453 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 | |
| SCHEMBL1201538 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 | |
| SCHEMBL318045 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 | |
| SCHEMBL1108059 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 | |
| SCHEMBL1108057 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 | |
| SCHEMBL1200906 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 | |
| SCHEMBL28765484 | 0.90 | PLA2G2A (0.66) | PLA2G2AALDH1A1HPGDPTPN11TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2711370-B1 | METHOD FOR PRODUCING OLIGONUCLEOTIDES | AJINOMOTO KK (JP) | 2018-01-03 | — | — | EP | disclosed |
| US-9029528-B2 | Solution-based method of making oligonucleotides via phosphoramidite coupling | AJINOMOTO CO., INC. (JP) | 2015-05-12 | — | — | US | disclosed |
| EP-2711370-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Ajinomoto Co., Inc. (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120296074-A1 | PRODUCTION METHOD OF OLIGONUCLEOTIDE | RNGTT, POLM, RNMT | PLA2G2A 3934/4885ALDH1A1 4056/4885HPGD 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.